Syngene International SYNGENE
India's largest CRO/CDMO - discovery, development and manufacturing for global pharma and biotech, including biologics
Mapped in 1 theme: Pharmaceuticals.
Where Syngene International sits in the supply chain
Syngene International appears in 1 supply-chain layer in one theme, Pharmaceuticals.
Pharmaceuticals › CDMO & contract research
Direct supplierOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 3,489 | 3,642 | 3,739 |
| Net profit | 510 | 496 | 317 |
Latest-year revenue ₹3,739 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- Deep, long-standing relationships with global pharma (Bristol Myers Squibb, Amgen and others)
- Added US biologics manufacturing (Baltimore site) and Bengaluru capacity
Risks
- FY26 profit fell 36% and the stock has fallen sharply in the year to Oct 2026 on weak biotech demand and large-molecule customer destocking
- Biologics capacity ramp-up dilutes returns on capital
Common questions
What does Syngene International do?
India's largest CRO/CDMO - discovery, development and manufacturing for global pharma and biotech, including biologics.
Where does Syngene International sit in the supply chain?
Syngene International (NSE: SYNGENE) is mapped in 1 supply-chain layer: CDMO & contract research (Pharmaceuticals).
Who are Syngene International's peers?
In the CDMO & contract research layer of Pharmaceuticals: Divi's Laboratories, Sai Life Sciences, Anthem Biosciences, Cohance Lifesciences, Piramal Pharma, Laurus Labs and 4 more.
What is Syngene International's market cap and valuation?
As of 30 Oct 2026: market cap ₹16,268 Cr, P/E 61.2x, ROCE 10.0%, ROE 7.8%, dividend yield 0.31%.